Welcome to the Instem Investor Centre


Instem (AIM:INS.L) is a leading provider of IT applications to the global early development healthcare market. The Group is focused on the early development sector of the drug and chemical research and development industry, from late discovery and lead optimisation through to the Phase I clinical evaluation stage.

Instem’s Early Development Applications (EDA’s) are used in evaluation studies to:

  • collect, analyse and report complex scientific data;
  • comply with regulatory reporting requirements;
  • improve quality, consistency and efficiency of information reporting; and
  • reduce the time of critical path R&D activities.

Instem’s solutions are supplied to an international blue chip customer base including AstraZeneca, GlaxoSmithKline and Charles River Laboratories.

Share price

Instem receives strong City backing for £5mln fundraise

It placed 2.5mln shares at 200p – a very small discount to the market price of the stock, which clos...

Instem CEO expects more deals after oversubscribed placing

Instem ( LON:INS ) has raised £5mln through an oversubscribed placing to further its acquisition ...

Instem CEO “actively looking” for acquisitions in 2016

Instem ( LON:INS ), is on the hunt for more deals after it provided an upbeat assessment of curre...

ROUND-UP: Numbers starting to add up for Instem

“The outlook remains positive both in terms of the general market backdrop, which is undergoing a ro...

Access New Research Note about Material Fundraising to Drive Growth

Featured Video

Instem CEO most excited by FDA electronic submission business

Instem is a robust business, with net cash and a valuable customer base delivering high levels of recurring revenue. The business continues to increase its strong global market share and is well positioned to take advantage of the structural changes in the drug development industry. Both the regulatory and fiscal environments continue to be favourable to Instem, driving demand for all areas of our product suite.

The recent acquisitions of Logos Technologies and Perceptive Instruments mark important strategic moves into the early phase clinical and in vitro R&D marketplaces whilst providing additional cross-selling opportunities. Our clients now have the ability to turn to Instem as a global supplier for their data management needs across broader segments. We will continue to expand the Group's reach into complementary scientific domains as part of our growth strategy.

Phil Reason,
Chief Executive